Sutro Biopharma (STRO) Enterprise Value (2018 - 2026)

Sutro Biopharma has reported Enterprise Value for 10 years, with the latest figure at -$141.4 million in Q4 2025.

• Quarterly Enterprise Value rose 55.37% year-over-year to -$141.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$141.4 million (up 55.37% YoY) and the FY2025 annual result came in at -$141.4 million, up 55.37% from the prior year.
• Enterprise Value grew to -$141.4 million in Q4 2025 per STRO's latest filing, from -$167.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$66.6 million in Q1 2022 and troughed at -$388.3 million in Q3 2024.
• A 5-year average of -$218.5 million and a median of -$212.7 million in 2021 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 69.74% in 2022, then tumbled 277.32% in 2023.
• Over 5 years, Enterprise Value stood at -$160.8 million in 2021, then slumped by 88.08% to -$302.3 million in 2022, then surged by 63.22% to -$111.2 million in 2023, then plunged by 184.96% to -$316.9 million in 2024, then surged by 55.37% to -$141.4 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$141.4 million, -$167.6 million, and -$205.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.